NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free BCRX Stock Alerts $4.21 -0.17 (-3.88%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.18▼$4.4250-Day Range$4.38▼$5.9252-Week Range$4.18▼$9.06Volume3.81 million shsAverage Volume3.32 million shsMarket Capitalization$867.89 millionP/E RatioN/ADividend YieldN/APrice Target$13.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioCryst Pharmaceuticals alerts: Email Address BioCryst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside229.4% Upside$13.83 Price TargetShort InterestBearish15.64% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.39Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.68) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector237th out of 909 stocksBiological Products, Except Diagnostic Industry34th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.64% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 2.4 News and Social Media Coverage News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioCryst Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows9 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More BCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Stock News HeadlinesApril 23, 2024 | americanbankingnews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Buy" by AnalystsApril 22, 2024 | finance.yahoo.comWith 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backingApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 22, 2024 | globenewswire.comBioCryst to Report First Quarter 2024 Financial Results on May 6April 21, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month Low at $4.44April 17, 2024 | morningstar.comBioCryst Pharmaceuticals Inc BCRXApril 17, 2024 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory AgencyApril 17, 2024 | markets.businessinsider.comBioCryst: Brazilian Health Regulatory Agency Approves ORLADEYO - Quick FactsApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 17, 2024 | americanbankingnews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Up 5.6% in MarchApril 17, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (BCRX)April 17, 2024 | finance.yahoo.comBioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyApril 16, 2024 | money.usnews.comBiocryst Pharmaceuticals Inc.April 14, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 6.3% April 3, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 25, 2024 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesMarch 18, 2024 | finance.yahoo.comBCRX Apr 2024 6.000 putMarch 17, 2024 | finance.yahoo.comBCRX Apr 2024 6.000 callMarch 17, 2024 | ca.finance.yahoo.comBCRX Apr 2024 9.000 callMarch 17, 2024 | ca.finance.yahoo.comBCRX Apr 2024 7.000 putMarch 16, 2024 | finance.yahoo.comBCRX Apr 2024 7.000 callMarch 16, 2024 | finance.yahoo.comBCRX Apr 2024 5.000 putMarch 5, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | investorplace.comHidden Penny Gems: 7 Stocks With Triple-Digit Growth ProspectsFebruary 28, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)See More Headlines Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/24/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees536Year Founded1986Price Target and Rating Average Stock Price Target$13.83 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+228.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-68.36% Pretax Margin-68.26% Return on EquityN/A Return on Assets-36.96% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.12 Sales & Book Value Annual Sales$331.41 million Price / Sales2.62 Cash FlowN/A Price / Cash FlowN/A Book Value($2.22) per share Price / Book-1.90Miscellaneous Outstanding Shares206,150,000Free Float197,079,000Market Cap$867.89 million OptionableOptionable Beta1.90 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jon P. Stonehouse (Age 63)CEO, President & Executive Director Comp: $1.15MMr. Anthony J. Doyle (Age 43)Senior VP, CFO & Treasurer Comp: $726.42kMs. Alane P. Barnes (Age 58)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $655.33kDr. William P. Sheridan MBBS (Age 69)Chief Development Officer Comp: $784.09kDr. Yarlagadda S. Babu (Age 71)Chief Discovery Officer Comp: $691.45kDr. Helen M. Thackray FAAP (Age 56)M.D., Chief Research & Development Officer Comp: $844kMr. Charles K. Gayer (Age 53)Senior VP & Chief Commercial Officer Comp: $643.43kMr. Michael L. Jones (Age 54)Executive Director of Finance & Principal Accounting Officer Mr. John D. Bluth (Age 51)Chief Communications Officer Ms. Stephanie AngeliniChief People OfficerMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKNovavaxNASDAQ:NVAXImmaticsNASDAQ:IMTXKyverna TherapeuticsNASDAQ:KYTXREGENXBIONASDAQ:RGNXView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 142,534 shares on 4/24/2024Ownership: 0.188%Rice Hall James & Associates LLCSold 45,716 shares on 4/23/2024Ownership: 1.044%Los Angeles Capital Management LLCBought 36,284 shares on 4/5/2024Ownership: 0.043%Vanguard Group Inc.Bought 2,371,401 shares on 3/11/2024Ownership: 8.617%Fisher Asset Management LLCSold 300,630 shares on 3/5/2024Ownership: 1.399%View All Insider TransactionsView All Institutional Transactions BCRX Stock Analysis - Frequently Asked Questions Should I buy or sell BioCryst Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks. What is BioCryst Pharmaceuticals' stock price target for 2024? 6 brokers have issued 12 month target prices for BioCryst Pharmaceuticals' shares. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's stock price to reach $13.83 in the next year. This suggests a possible upside of 229.4% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts. How have BCRX shares performed in 2024? BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of 2024. Since then, BCRX shares have decreased by 29.9% and is now trading at $4.20. View the best growth stocks for 2024 here. Are investors shorting BioCryst Pharmaceuticals? BioCryst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 32,250,000 shares, an increase of 5.6% from the March 15th total of 30,550,000 shares. Based on an average daily trading volume, of 3,290,000 shares, the short-interest ratio is currently 9.8 days. View BioCryst Pharmaceuticals' Short Interest. When is BioCryst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our BCRX earnings forecast. How can I listen to BioCryst Pharmaceuticals' earnings call? BioCryst Pharmaceuticals will be holding an earnings conference call on Monday, May 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Monday, February, 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.04. The biotechnology company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million. What ETFs hold BioCryst Pharmaceuticals' stock? ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP) and iShares Genomics Immunology and Healthcare ETF (IDNA).LeaderShares Activist Leaders ETF (ACTV). What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (1.04%), Assenagon Asset Management S.A. (0.19%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCRX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
